Sharekhan's research report on Cadila Healthcare
Cadila’s quarterly performance adjusted for one-offs was better than our expectation. Moraiya facility classified as OAI by USFDA to remain an overhang until resolved.
Outlook
We maintain our Hold rating on the stock with marginally downward revised PT of Rs. 275. Biologics and vaccines business to propel growth and profitability from FY2021E.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
